ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
- PMID: 29454854
- DOI: 10.1016/j.pharmthera.2018.02.007
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Abstract
The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is de-regulated in a variety of cancers due to mutations in receptor tyrosine kinases (RTKs), negative regulators of RAS (such as NF1) and core pathway components themselves (RAS, BRAF, CRAF, MEK1 or MEK2). This has driven the development of a variety of pharmaceutical agents to inhibit RAF-MEK1/2-ERK1/2 signalling in cancer and both RAF and MEK inhibitors are now approved and used in the clinic. There is now much interest in targeting at the level of ERK1/2 for a variety of reasons. First, since the pathway is linear from RAF-to-MEK-to-ERK then ERK1/2 are validated as targets per se. Second, innate resistance to RAF or MEK inhibitors involves relief of negative feedback and pathway re-activation with all signalling going through ERK1/2, validating the use of ERK inhibitors with RAF or MEK inhibitors as an up-front combination. Third, long-term acquired resistance to RAF or MEK inhibitors involves a variety of mechanisms (KRAS or BRAF amplification, MEK mutation, etc.) which re-instate ERK activity, validating the use of ERK inhibitors to forestall acquired resistance to RAF or MEK inhibitors. The first potent highly selective ERK1/2 inhibitors have now been developed and are entering clinical trials. They have one of three discrete mechanisms of action - catalytic, "dual mechanism" or covalent - which could have profound consequences for how cells respond and adapt. In this review we describe the validation of ERK1/2 as anti-cancer drug targets, consider the mechanism of action of new ERK1/2 inhibitors and how this may impact on their efficacy, anticipate factors that will determine how tumour cells respond and adapt to ERK1/2 inhibitors and consider ERK1/2 inhibitor drug combinations.
Keywords: BRAF; Cancer; ERK; Inhibitors; MEK; RAS.
Copyright © 2018. Published by Elsevier Inc.
Similar articles
-
Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.Biochem J. 2024 Mar 20;481(6):405-422. doi: 10.1042/BCJ20240015. Biochem J. 2024. PMID: 38381045 Free PMC article.
-
Targeting ERK1/2 protein-serine/threonine kinases in human cancers.Pharmacol Res. 2019 Apr;142:151-168. doi: 10.1016/j.phrs.2019.01.039. Epub 2019 Feb 20. Pharmacol Res. 2019. PMID: 30794926 Review.
-
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15. Pharmacol Res. 2018. PMID: 30118796 Review.
-
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.Nat Rev Cancer. 2015 Oct;15(10):577-92. doi: 10.1038/nrc4000. Nat Rev Cancer. 2015. PMID: 26399658 Review.
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902. Nature. 2010. PMID: 20179705 Free PMC article.
Cited by
-
Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.Biochem J. 2024 Mar 20;481(6):405-422. doi: 10.1042/BCJ20240015. Biochem J. 2024. PMID: 38381045 Free PMC article.
-
Pathological roles of bone marrow adipocyte-derived monocyte chemotactic protein-1 in type 2 diabetic mice.Cell Death Discov. 2023 Nov 13;9(1):412. doi: 10.1038/s41420-023-01708-3. Cell Death Discov. 2023. PMID: 37957155 Free PMC article.
-
HPIP is an essential scaffolding protein running through the EGFR-RAS-ERK pathway and drives tumorigenesis.Sci Adv. 2023 Jun 9;9(23):eade1155. doi: 10.1126/sciadv.ade1155. Epub 2023 Jun 9. Sci Adv. 2023. PMID: 37294756 Free PMC article.
-
ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1.Biochem J. 2023 May 15;480(9):587-605. doi: 10.1042/BCJ20220598. Biochem J. 2023. PMID: 37018014 Free PMC article.
-
The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target.Front Immunol. 2023 Mar 13;14:1094823. doi: 10.3389/fimmu.2023.1094823. eCollection 2023. Front Immunol. 2023. PMID: 36993955 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- BBS/E/B/0000C199/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- BBS/E/B/000C0417/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- 12-1259/AICR_/Worldwide Cancer Research/United Kingdom
- 14867/CRUK_/Cancer Research UK/United Kingdom
- A14867/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous